Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer…
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a…
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…
These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),…
Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…
A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to…
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL…
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian…